POD12在血管免疫母性T细胞淋巴瘤中的预后意义

The Prognostic Significance of POD12 in Angioimmunoblastic T-cell Lymphoma

目的探讨12个月内疾病进展(POD12)对血管免疫母性T细胞淋巴瘤(AITL)患者总生存期(OS)的影响。方法回顾性分析2010年1月-2021年9月在徐州医科大学附属医院血液科就诊的初诊并化疗的AITL患者29例,根据12个月内原发病是否进展,分为POD12组(19例)与非POD12组(10例),比较两组临床特征及生存状况,分析影响AITL患者OS的危险因素。结果两组年龄、性别、Ann-Arbor分期、B症状、乳酸脱氢酶水平及血红蛋白水平等临床特征比较,差异均无统计学意义(P>0.05);POD12组中位OS短于非POD12组,5年OS率低于非POD12组,差异均有统计学意义(P<0.05);多因素分析显示,血红蛋白<120 g/L和POD12是影响AITL患者OS的独立危险因素。结论POD12是AITL患者的独立预后不良因素,可用于筛选高危患者及指导治疗。

Objective To investigate the effect of disease progression within 12 months(POD12)on overall survival(OS)in patients with angioimmu-noblastic T cell lymphoma(AITL).Methods A retrospective analysis of 29 patients with AITL who were newly diagnosed and treated with chemotherapy in the Department of Hematology,Affiliated Hospital of Xuzhou Medical University from January 2010 to September 2021 was divided into POD12 group(19 cases)and non-POD12 group(10 cases)according to whether the primary disease progressed within 12 months.The clinical characteristics and survival status of the two groups were compared,and the risk factors affecting OS of AITL patients were analyzed.Results There were no significant differences in age,sex,Ann-Arbor stage,B symptoms,lactate dehydrogenase level and hemoglobin level between the two groups(P>0.05).The median OS of the POD12 group was shorter than that of the non-POD 12 group,and the 5-year OS rate was lower than that of the non-pod12 group,the differences were statistically significant(P<0.05).Multivariate analysis showed that hemoglobin<120 g/L and POD12 were independent risk factors for OS in patients with AITL.Conclusion POD12 is an independent poor prognostic factor for AITL patients,which can be used to screen high-risk patients and guide treatment.